





 Synthesis of 18O-Labelled Alcohols from Unlabelled Alcohols 
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Denton*a 
The synthesis of primary, secondary and tertiary 18O-enriched alcohols from readily available 16O-alcohols via a Mitsunobu esterification 
and hydrolysis is described. The method is further exemplified in the labelling of the active pharmaceutical ingredient, Dropropizine and 
is shown to be tolerant of modern, separation friendly Mitsunobu reagents.  
Stable isotope-labelled compounds have a variety of roles in organic chemistry and the biomedical sciences. For example, they are used to 
probe reaction mechanisms through the determination of kinetic isotope effects and isotope labelling experiments.1 In pharmaceutical 
development, stable isotope-labelled compounds are widely used as internal standards for mass-spectrometry based analysis of 
pharmacokinetics and pharmacodynamics.2 Additionally, isotope incorporation, notably deuterium, can improve the metabolic stability of 
active pharmaceutical ingredients.3  
The synthesis of stable isotope-labelled active pharmaceutical ingredients is usually achieved by de novo syntheses using building blocks 
enriched with a specific stable isotope (most commonly 2H, 13C or 15N). Although oxygen-containing functional groups are common in 
pharmaceutical molecules, compounds containing 18O are rare,4 due to the poor availability of 18O-enriched building blocks.2b In most cases, 
18O-enriched alcohols are accessed using bespoke, substrate-specific syntheses.5 To the best of our knowledge, only two general methods of 
accessing 18O-enriched alcohols have been reported to date. Nakamura et al. disclosed a method for converting alkyl iodides and bromides 
to 18O-enriched alcohols (Fig. 1A).6 The reaction occurs through tin hydride-mediated generation of a radical, which is trapped with 18O2 
followed by reduction. In 2013, Rozen and co-workers reported the oxidative conversion of boronic acids into 18O-enriched alcohols using 
the hypofluorous acid complex [H18OF•MeCN] (Fig. 1B).7 This unusual reagent is prepared from fluorine gas, 18O-enriched water and 
acetonitrile. 
Despite these encouraging reports we reasoned that a new method, using readily available non-labelled alcohols as substrates, would 
be of value and provide a general route to stereodefined 18O-enriched alcohols for mechanistic studies.8 Herein, we report a simple and 
practical protocol based on a Mitsunobu reaction9 using an 18O-enriched carboxylic acid followed by hydrolysis (Scheme 1C).  
Figure 1 Approaches to the synthesis of 18O-enriched alcohols. (A) Nakamura’s tin 
hydride mediated synthesis from alkyl bromides and alkyl iodides. (B) Rozen’s 
[H18OF•MeCN] mediated oxidation of boronic acids. (C) This work: A Mitsunobu 
esterification-hydrolysis strategy using an 18O-labelled carboxylic acid.
We began by investigating the synthesis of 4-nitrobenzoic acid-[18O]2 (2) by an acid-mediated hydrolysis of 4-nitrobenzonitrile (4) using 
18O-enriched water. 4-Nitrobenzoic acid was chosen as a suitable carboxylic acid as it is a very commonly used in the Mitsunobu reaction.10 
A short optimisation sequence (see supplementary information, Table S1 and S2) revealed that the hydrolysis of 4-nitrobenzonitrile in 4 M 
HCl in dioxane afforded 89% of the corresponding doubly 18O-labelled carboxylic acid with an isotopic purity of 93%. The only other 
isotopologue detected was the singly labelled acid, which accounted for the remaining 7%. In this protocol, 4-nitrobenzoic acid-[18O]2 was 
isolated by filtration and used directly in the Mitsunobu esterification step without further purification. 
With a convenient method to access 4-nitrobenzoic acid-[18O]2 (2) in hand, we explored the scope of the labelling protocol with a range 
of alcohol substrates. Firstly, benzylic alcohols substrates were examined and both 1-naphthalenemethanol (1a) and sulfone-containing 
substrate 1b were converted into the corresponding isotopologues with excellent levels of 18O enrichment. Additionally, the 18O 
isotopologues for indole-containing alcohol 1c and amino acid derivative 1d were accessed in moderate-to excellent yields and with high 
levels of 18O enrichment. Ferrocenemethanol (1e) and sugar derivative 1f were also efficiently labelled—the slightly lower level of 18O 
enrichment for 1e being possibly attributable to post hydrolysis SN1-type hydroxyl exchange. The enrichment of monoterpenoids, namely 
geraniol (1g) and (1R)-(−)-myrtenol (1h) was also investigated, and the 18O-enriched products (3g and 3h) were isolated with good yields and 
excellent levels of 18O incorporation. 18O-enriched (±)-neomenthol (3i) was obtained when (±)-menthol (1i) was subjected to the reaction 
conditions, demonstrating the expected inversion of stereochemistry associated with the Mitsunobu esterification. Similarly, epi-cholesterol-
[18O] (3k) was obtained from natural cholesterol (1k). Finally, the 18O-isotopologue of acetal-protected adenosine 1l was produced with 
excellent 18O enrichment albeit with a poor yield. Although the yields of different substrates were variable the 18O enrichment for each 
example remained excellent throughout, ranging from 87–96%. 
We next sought to extend this method to encompass active pharmaceutical ingredients. In the context of deuterium labelling, recent 
developments in hydrogen/deuterium exchange reactions have enabled straightforward access to deuterium-labelled pharmaceuticals.11 
Figure 2 Substrate scope for the Mitsunobu esterification-hydrolysis mediated synthesis of 18O-enriched alcohols. Yields are quoted as overall yield of the two-step process. 
a 18O-enrichment is quoted as the mol% of sample enriched with two 18O labels. b K2CO3 in MeOH/H2O was used for the hydrolysis step. 
This approach, whereby certain hydrogen atoms of a pharmaceutical are exchanged for deuterium, offers a cost- and time-efficient 
alternative to de novo synthesis. We therefore wished to apply this principle to 18O-enriched active pharmaceutical ingredients. Generally, 
for stable-isotope analogues of active pharmaceutical ingredients to serve as internal standards, the most abundant isotopologue is required 
to be at least four mass units heavier than the unlabelled isotopologue ([M0 + 4]). In the context of 18O labels, the most abundant isotopologue 
of an internal standard must contain a minimum of two 18O labels. Furthermore, the internal standard should contain no greater than 0.5% 
of the parent, unlabelled isotopologue ([M0]) in order to avoid cross-signal interferences.12  
The cough suppressant, Dropropizine, was chosen as an appropriate example, since it contains two hydroxyl groups that are reactive 
towards a Mitsunobu esterification reaction. Using our standard protocol, we were able to obtain Dropropizine-[18O]2 in an overall yield of 
56%. Mass spectrometry analysis of this sample indicated that the doubly-labelled isotopologue ([M0 + 4]) accounted for 90.3% of the sample, 
the singly-labelled isotopologue ([M0 + 2]) accounted for 9.4%, and only 0.3% of the unlabelled substrate ([M0]) was present, thus 
demonstrating that our method can be effectively used as a means to access these mass spectrometry internal standards. 
The classical Mitsunobu conditions (DIAD and triphenylphosphine), used in this study suffer from well-documented drawbacks, 
specifically the production of triphenylphosphine oxide and hydrazine by-products. Furthermore, DIAD is thermally unstable and its use 
should be avoided on scale.13 Therefore we explored the use of second-generation Mitsunobu reagents14 in our 18O-labelling protocol.  
Firstly, the use of di-tert-butyl azodicarboxylate (DTBAD) in conjunction with diphenyl-2-pyridylphosphine,15 followed by hydrolysis, 
enabled the 18O-enrichment of 1-naphthalenemethanol with comparable efficiency to the DIAD/triphenylphosphine system (Fig. 3A, Entry 
2). Under these conditions, addition of hydrochloric acid coverts the hydrazine by-product into gaseous products and allows the phosphine 
oxide to be removed by phase-separation. Similarly, the use of di-(4-chlorobenzyl)azodicarboxylate (DCAD) developed by Lipshutz16 with 
polystyrene-supported triphenylphosphine (PS-PPh3), followed by hydrolysis, afforded 1-naphthalenemethanol-[18O] with comparable 18O 
enrichment (92%) but with a lower yield of 49% (Fig. 3A, Entry 3). Both the hydrazine and phosphine oxide by-products of this reaction are 
insoluble in dichloromethane and were separated from the reaction mixture by filtration. 
Using Tsunoda’s reagent (cyanomethylenetributylphosphorane, CMBP),17 instead of DIAD and triphenylphosphine, afforded 
1-naphthalenemethanol-[18O] with excellent 18O enrichment (Fig. 3A, Entry 4).  Furthermore, the commonly used combination of 1,1’-
(azodicarbonyl)dipiperidine (ADDP) and tributylphosphine (Fig. 3A, Entry 5),18 followed by hydrolysis, also afforded 1-naphthalenemethanol-
[18O] albeit with reduced yield and isotopic enrichment. Overall, these experiments demonstrate that the use of the potentially hazardous 
Figure 3 (A) The use of alternative, separation friendly Mitsunobu reagents in the 
Mitsunobu esterification-hydrolysis protocol. (B) The derivatisation of 18O-enriched 
secondary alcohols into tertiary alcohol. 
DIAD, and the chromatographic removal of the phosphine oxide and hydrazine by-products can be avoided in our Mitsunobu labelling 
protocol.  
Finally, we turned our attention to the synthesis of 18O-enriched tertiary alcohols, which are hard to prepare by direct Mitsunobu 
reactions.19 Oxidation of 18O-enriched alcohol 3j to the corresponding ketone using Dess-Martin periodinane,20 followed by a Grignard 
addition using 2-methoxyphenylmagnesium bromide afforded the tertiary alcohol 5 in a yield of 67% over two steps with minimal erosion of 
the 18O enrichment (Fig. 3B).  
In conclusion, an operationally simple synthesis of 18O-enriched primary, secondary and tertiary alcohols has been developed. The 
Mitsunobu coupling approach allows abundant unlabelled alcohols to be used as substrates whilst also providing stereocontrol. The 
conditions were shown to be tolerant of a wide range of functional groups and were also applied to the synthesis of an isotopically labelled 
active pharmaceutical ingredient. Furthermore, we have demonstrated that alternative Mitsunobu reagents, which simplify purification, are 
compatible with this protocol. We envision that this method will be useful as a general and practical means of accessing a broad range of 
18O-enriched alcohols. 
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